3rd Annual Hematologic Malignancies Symposium

 

3rd Annual Hematologic Malignancies Symposium
C

MD Anderson Update on the Role of IDH Inhibition in AML: Targeted Therapy Strategies and Outcomes

By 3rd Annual Hematologic Malignancies Symposium FEATURING Courtney D. DiNardo
By 3rd Annual Hematologic Malignancies Symposium FEATURING Courtney D. DiNardo
231 views
April 8, 2021
Comments 0
Login to view comments. Click here to Login
Videos
26:33

2021 Updates on FLT3m Frontline AML: Does HiDAC+Chemo Provide OS Ben…

3rd Annual Hematologic Malignancies Symposium

A. Perl

144 views
07:34

2021 Updates on FLT3m R/R AML: What Is the Current Standard of Care?…

3rd Annual Hematologic Malignancies Symposium

A. Perl

216 views
15:35

How I Treat Elderly AML Patients in 2021: Does Midostaurin Improve O…

3rd Annual Hematologic Malignancies Symposium

G. Roboz

126 views
22:10

MD Anderson Update on the Role of IDH Inhibition in AML: Targeted Th…

3rd Annual Hematologic Malignancies Symposium

C. DiNardo

231 views
26:23

HMA Resistance & Treatment After HMT Failure in MDS: Aza vs. CCR, In…

3rd Annual Hematologic Malignancies Symposium

H. Carraway

128 views
15:41

IDH Inhibitors in MDS: Frequency & Prognosis, Mutations, Therapy Out…

3rd Annual Hematologic Malignancies Symposium

A. Wei

418 views